Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Dabrafenib + Trametinib |
Indication/Tumor Type | papillary craniopharyngioma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | papillary craniopharyngioma | predicted - sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in a 95% decrease in tumor size in a patient with papillary craniopharyngioma harboring BRAF V600E (PMID: 35023192). | 35023192 |
BRAF V600E | papillary craniopharyngioma | predicted - sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, neoadjuvant treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in sustained radiologic response after 3 months of treatment followed by a tumor-free period lasting 2 years from treatment discontinuation in a patient with papillary craniopharyngioma harboring BRAF V600E (PMID: 37683921). | 37683921 |
BRAF V600E | papillary craniopharyngioma | predicted - sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in decreased tumor size and symptom improvement in a patient with recurrent papillary craniopharyngioma harboring BRAF V600E, with treatment ongoing for at least 7 months (PMID: 28425764). | 28425764 |
BRAF V600E | papillary craniopharyngioma | predicted - sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, Tafinlar (dabrafenib) treatment resulted in a 70% cyst volume reduction and 52% decreased enhancing volume followed by combination treatment with Mekinist (trametinib) resulting in 81% cyst volume reduction and 85% enhancing volume reduction in a patient with recurrent papillary craniopharyngioma harboring BRAF V600E (PMID: 26498373). | 26498373 |
PubMed Id | Reference Title | Details |
---|---|---|
(28425764) | BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. | Full reference... |
(37683921) | Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma. | Full reference... |
(35023192) | Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift. | Full reference... |
(26498373) | Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. | Full reference... |